The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
The Lead
PhRMA Names New Head of Policy & Research Department
May 22, 2013 8:44 am | News | Comments
The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Lori Reilly will become Executive Vice President of Policy and Research, effective June 7, 2013. She succeeds Rick Smith, who will retire after 11 years of service with PhRMA. Reilly will report directly to PhRMA President and CEO John Castellani and serve as a member of the PhRMA Management Committee.
Pfizer Announces Plan for Split-Off of Zoetis
May 22, 2013 8:15 am | News | Comments
Pfizer Inc. today announced its intention to split off its remaining interest in Zoetis Inc.,...
Study: New Drug May Help Some Asthmatics
May 22, 2013 8:01 am | by By Andrew Pollack, New York Times News Service | News | Comments
A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may...
Merck to Repurchase $5B in Common Stock
May 21, 2013 5:41 pm | by The Associated Press | News | Comments
WHITEHOUSE STATION, N.J. (AP) — Merck & Co Inc. said it will repurchase $5 billion worth of...
FREE Daily Email Newsletter
Vibrating Mixer
May 22, 2013 3:56 pm | Product Releases | CommentsUnit produces the mixing effect by vibration transmitted from an electro-magnetic drive to a perforated plate with several conical holes. Due to the Bernoulli effect, this vibration causes the liquid to be pumped upward or downward through the holes. It can be used in open or closed tanks under sterile conditions and vacuum.
Inflatable Seal Compounds
May 22, 2013 3:49 pm | Product Releases | CommentsThe CVI™ Series is especially designed for inflatable seals used in a wide range of pharmaceutical and medical seal applications. The compounds are available in silicone and EPDM. USP Class VI certification, the most stringent protocol for classification of compounds used in medical and other healthcare applications.
Powder and Liquid Processing System
May 22, 2013 1:43 pm | Product Releases | CommentsThe Ystral Conti-TDS features powder induction, wetting and then dispersing of an agglomerate-free liquid – all with one machine. The patented Conti-TDS system operates dust-free and loss-free. The Conti-TDS process allows better reactivity and higher efficiencies for the raw material resulting in a higher quality end product with no agglomeration. It also minimizes production time and completely avoids partial processing steps, thereby minimizing costs.
Cancer Society Hits 100 as US Cancer Rate Falls
May 22, 2013 8:08 am | by MIKE STOBBE,AP Medical Writer | News | CommentsThe American Cancer Society — one of the nation's best known and influential health advocacy groups — is 100 years old this week. Back in 1913 when it was formed, cancer was a lesser threat for most Americans. The biggest killers then were flu, pneumonia, tuberculosis, and stomach bugs. At a time when average life expectancy was 47, few lived long enough to get cancer.
Biogen Submits New MS Drug for FDA Approval
May 21, 2013 4:11 pm | News | CommentsBiogen Idec has submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The drug, called Plegridy, is intended to treat patients with relapsing forms of multiple sclerosis, a disease of the immune system in which the body attacks the brain and spinal cord.
Double Planetary Mixers
May 21, 2013 3:30 pm | Product Releases | CommentsThe new agitator blade is designed for the line of double planetary mixers. The 100-gallon model is equipped with two identical rectangular stirrers with upward rake fingers. Designed to rotate on their own axes while orbiting the vessel on a common axis, these style blades are ideal for batching dry powder blends, wet granulations and similar formulations in the double planetary mixers.
French Drugmaker on Trial, Suspected in Deaths
May 21, 2013 2:51 pm | News | CommentsThe makers of a diabetes and weight loss drug suspected in the deaths of hundreds of people went on trial Tuesday, facing charges they misled the public about the product's safety. But after years of delays in one of France's biggest recent health scandals, the proceedings could still be pushed back further.
Industrial Camera
May 21, 2013 2:44 pm | Product Releases | CommentsThe Cognex Industrial Camera (CIC) series has a new line of GigE Vision® digital industrial cameras designed for easy integration with VisionPro® and CVL® vision software. The first four models of the CIC series are compact, monochrome, area scan cameras.
Taking Meds Goes High-Tech
May 21, 2013 12:11 pm | Videos | CommentsStartups are coming up with new technologies, such as "digital pills" and social games with rewards, aimed at getting people to take medicine only as directed. A range of startup companies are trying to use technology to come up with more cost-effective ways to get medication used properly.
AcelRx Pain Treatment Meets Late-Stage Study Goals
May 21, 2013 11:30 am | by The Associated Press | News | CommentsShares of AcelRx Pharmaceuticals Inc. hit an all-time high price Tuesday, after the specialty drugmaker said its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval. The Redwood City, Calif., company said...
Peregrine Rises on Agreement for Late-Stage Study
May 21, 2013 8:44 am | News | CommentsShares of Peregrine Pharmaceuticals surged Monday after the company said it would move ahead with a late-stage trial of its lead product, the experimental lung cancer treatment bavituximab. Peregrine said in a release it reached an agreement with the Food and Drug Administration on a phase III study of its drug involving 600 patients.
XenoPort MS Treatment Fails in Late-Stage Testing
May 21, 2013 8:18 am | by The Associated Press | News | CommentsShares of XenoPort Inc. sank Monday after the drug developer said a potential treatment for multiple sclerosis patients failed in late-stage clinical testing, and it will stop developing the drug. The Santa Clara, Calif., company said the treatment, labeled arbaclofen placarbil, failed to show a statistically significant improvement for patients taking it compared to a fake drug.
Royalty Pharma Increases Bid for Elan
May 21, 2013 8:13 am | News | CommentsRoyalty Pharma has raised its offer to buy Elan on the condition that shareholders reject the Irish drugmaker's push to refocus its business through a string of recently announced deals, including two new deals unveiled Monday. Royalty said Monday it will pay $12.50 in cash for each share of Elan Corp. PLC. That adds up to a total value of about $7.5 billion.
Drought Accelerates Use of Drugs to Beef Up Cattle
May 21, 2013 8:10 am | by ROXANA HEGEMAN,Associated Press | News | CommentsCattle feeders in the U.S. are coping with reduced herds and high corn costs in part by increasing their use of growth-inducing drugs designed to bulk up animals, get more pounds of beef from each carcass and circumvent the drought's withering effects on the food cycle.
Novo A/S acquires Xellia Pharmaceuticals for $700 million
May 21, 2013 8:03 am | News | CommentsXellia Pharmaceuticals, a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced today that Novo A/S, the holding company of the Novo Group, has purchased all shares of the group for approximately US$ 700 million from 3i and other current shareholders.
